After observing an increase in the expression of HDAC6 both at the mRNA level and at the protein level (Figure 2) in tumor tissues versus healthy tissues and in the cell lines derived from glioblastoma versus the cell line of normal astrocytes (NHA), we set out to modulate their expression through the use of siRNA to see the effect that silencing could have on the oncogenic capacity of glioblastoma tumor lines. The gene discussed is HDAC6; the disease is glioblastoma.